» Articles » PMID: 39157206

Recent Advances in Minimally Invasive Biomarkers of OSCC: from Generalized to Personalized Approach

Overview
Date 2024 Aug 19
PMID 39157206
Authors
Affiliations
Soon will be listed here.
Abstract

Oral cancer is the 6th most common type of cancer worldwide, and oral squamous cell carcinoma (OSCC) accounts for >90% of oral cancers. It is a major health problem, particularly in low- and middle-income countries (LMICs), due to both its high incidence and significant mortality and morbidity. Despite being a global burden, and even with the significant advancement in the management of OSCC, the overall outcome of the disease is still abysmal. With the advent of time, advanced diagnostic and treatment approaches have come into practice, but the burden of the disease has not improved significantly. Major reasons attributed to the poor outcome are delay in diagnosis, locoregional recurrence and resistance to the currently available treatment regimen. In this review, we have highlighted the existing challenges in the diagnosis and have emphasized the advancements in minimally invasive biomarkers. Additionally, the importance of collaborative multidimensional approaches involving clinicians and researchers has been discussed, as well as the need to redefine and establish better utility and management of existing diagnostic and treatment protocols along with the minimally invasive/non-invasive biomarkers.

Citing Articles

Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway.

Wang C, Wu Z, Zhou J, Cheng B, Huang Y J Cancer Res Clin Oncol. 2025; 151(3):103.

PMID: 40055197 PMC: 11889073. DOI: 10.1007/s00432-025-06154-5.


The role of molecular biomarkers in the diagnosis, prognosis, and treatment stratification of oral squamous cell carcinoma: A comprehensive review.

Ravindran S, Ranganathan S, R K, J N, A S, Kannan S J Liq Biopsy. 2025; 7:100285.

PMID: 40027232 PMC: 11863969. DOI: 10.1016/j.jlb.2025.100285.


Current trends on prevalence, risk factors and prevention of oral cancer.

Coletta R, Yeudall W, Salo T Front Oral Health. 2024; 5:1505833.

PMID: 39606098 PMC: 11599248. DOI: 10.3389/froh.2024.1505833.

References
1.
Elhendawy H . Clinical implications of heat shock protein 70 in oral carcinogenesis and prediction of progression and recurrence in oral squamous cell carcinoma patients: a retrospective clinicopathological study. Eur J Med Res. 2023; 28(1):464. PMC: 10604814. DOI: 10.1186/s40001-023-01433-8. View

2.
Lopes V, Souza de Jesus A, de Souza L, Miyahara L, Guimaraes D, Pontes H . Ki-67 protein predicts survival in oral squamous carcinoma cells: an immunohistochemical study. Braz Oral Res. 2017; 31:e66. DOI: 10.1590/1807-3107BOR-2017.vol31.0066. View

3.
La Thangue N, Kerr D . Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol. 2011; 8(10):587-96. DOI: 10.1038/nrclinonc.2011.121. View

4.
Radhakrishnan V, Kaifi J, Suvilesh K . Circulating Tumor Cells: How Far Have We Come with Mining These Seeds of Metastasis?. Cancers (Basel). 2024; 16(4). PMC: 10887304. DOI: 10.3390/cancers16040816. View

5.
Arora R, Haynes L, Kumar M, McNeil R, Ashkani J, Nakoneshny S . NCBP2 and TFRC are novel prognostic biomarkers in oral squamous cell carcinoma. Cancer Gene Ther. 2023; 30(5):752-765. PMC: 10191846. DOI: 10.1038/s41417-022-00578-8. View